Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266917 | 0.97 | KDM4E (0.53) | KDM4ENPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13266949 | 0.92 | KDM4E (0.54) | KDM4ENPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13267514 | 0.92 | KDM4E (0.48) | KDM4ENPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13245276 | 0.90 | MMP13 (0.47) | KDM4E | |
| SCHEMBL3007908 | 0.89 | MMP13 (0.55) | — | |
| SCHEMBL13984670 | 0.89 | KDM4E (0.55) | KDM4ENPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13266889 | 0.89 | KDM4E (0.55) | KDM4ENPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13245313 | 0.86 | MMP13 (0.47) | KDM4E | |
| SCHEMBL3018972 | 0.86 | MMP13 (0.56) | — | |
| SCHEMBL3018980 | 0.86 | MMP13 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | KDM4E 4299/4885NPC1 299/4885RAB9A 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.